Prudential Financial
KPTI icon

Prudential Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Prudential Financial’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,973
Closed -$50.5K – 2340
2024
Q4 		$50.5K Hold
4,973
– – ﹤0.01% 2209
2024
Q3 		$61.9K Buy
+4,973
New +$61.8K ﹤0.01% 2622
2024
Q2 		– Sell
-1,308
Closed -$29.6K – 2749
2024
Q1 		$29.6K Sell
1,308
-346
-21% -$6.07K ﹤0.01% 2633
2023
Q4 		$21.5K Buy
1,654
+360
+28% +$4.85K ﹤0.01% 2612
2023
Q3 		$26K Buy
+1,294
New +$29K ﹤0.01% 2558
2023
Q1 		– Sell
-920
Closed -$46.9K – 2634
2022
Q4 		$46.9K Sell
920
-1,193
-56% -$82.7K ﹤0.01% 2495
2022
Q3 		$173K Sell
2,113
-1,320
-38% -$98.6K ﹤0.01% 2470
2022
Q2 		$232K Buy
+3,433
New +$315K ﹤0.01% 2423
2019
Q2 		– Sell
-5,902
Closed -$517K – 2472
2019
Q1 		$517K Buy
5,902
+1,000
+20% +$111K ﹤0.01% 2077
2018
Q4 		$689K Buy
4,902
+3,434
+234% +$579K ﹤0.01% 1924
2018
Q3 		$375K Sell
1,468
-32
-2% -$8.85K ﹤0.01% 2122
2018
Q2 		$382K Sell
1,500
-3,082
-67% -$762K ﹤0.01% 2115
2018
Q1 		$923K Buy
4,582
+3,307
+259% +$659K ﹤0.01% 1874
2017
Q4 		$184K Buy
+1,275
New +$205K ﹤0.01% 2270

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Prudential Financial's KPTI Position: Q1 2025 in Review

Prudential Financial sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 4,973 shares — an estimated $50.5K sold.

Prudential Financial first reported a position in KPTI in Q4 2017 and held it in 14 quarters. The position peaked at $923K in Q1 2018. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Prudential Financial reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Prudential Financial sold 4,973 Karyopharm Therapeutics shares in Q1 2025, an estimated $50.5K.
  • Prudential Financial first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 14 quarters.
  • Prudential Financial's Karyopharm Therapeutics position peaked at $923K in Q1 2018.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Prudential Financial's 13F filing for Q1 2025, filed 13 May 2025.